BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jazz Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Jazz Pharmaceuticals's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06695845-2201@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT06695845)
DESCRIPTION:Zanidatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06695845
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625280-11034@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20271223
DTEND;VALUE=DATE:20271224
SUMMARY:Calcium\, magnesium\, potassium and sodium oxybates (Xywav): Phase 
 3 readout est. (NCT07625280)
DESCRIPTION:Calcium\, magnesium\, potassium and sodium oxybates (Xywav)\, p
 hase 3\, Narcolepsy.\nStudy: A Study Evaluating the Efficacy and Safety of
  Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH\nE
 stimated primary completion: 23 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxybates-
 xywav#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07625280
URL:https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxyba
 tes-xywav#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102381-2201@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07102381)
DESCRIPTION:Zanidatamab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A 
 Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy 
 in Participants With HER2-positive Breast Cancer\nEstimated primary comple
 tion: 29 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07102381
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496048-2601@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06496048)
DESCRIPTION:Lurbinectedin\, phase 3\, Small Cell Lung Cancer.\nStudy: Lurbi
 nectedin or in Combination with Irinotecan Versus Topotecan in Patients wi
 th Relapsed SCLC\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06496048
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05734066-2601@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT05734066)
DESCRIPTION:Lurbinectedin\, phase 1/2.\nStudy: Study of Lurbinectedin Monot
 herapy in Pediatric and Young Adult Participants With Relapsed/Refractory 
 Ewing Sarcoma\nEstimated primary completion: 28 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05734066
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-2201@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Zanidatamab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: A 
 Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Ea
 ch in Combination With Physician's Choice Chemotherapy\, for the Treatment
  of Participants With Metastatic HER2-positive Breast Cancer\nEstimated pr
 imary completion: 28 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05580562-3224@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dordaviprone: Phase 3 readout est. (NCT05580562)
DESCRIPTION:Dordaviprone\, phase 3\, Glioma.\nStudy: ONC201 in H3 K27M-muta
 nt Diffuse Glioma Following Radiotherapy (the ACTION Study)\nEstimated pri
 mary completion: June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dordaviprone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05580562
URL:https://assetmemo.bio/drug/dordaviprone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723963-8942@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Cannabidiol (JZP926): Phase 2/3 readout est. (NCT07723963)
DESCRIPTION:Cannabidiol (JZP926)\, phase 2/3\, Epilepsy.\nStudy: A Study to
  Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of J
 uvenile Myoclonic Epilepsy\nEstimated primary completion: 1 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-jzp926#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0772396
 3
URL:https://assetmemo.bio/drug/cannabidiol-jzp926#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-2201@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Zanidatamab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficacy 
 and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-o
 f-care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimated 
 primary completion: 1 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459634-2601@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20290804
DTEND;VALUE=DATE:20290805
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07459634)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stu
 dy of Lurbinectedin in Combination With Durvalumab for the Treatment of Pa
 rticipants With ES-SCLC\nEstimated primary completion: 4 August 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07459634
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06088290-2601@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20290830
DTEND;VALUE=DATE:20290831
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06088290)
DESCRIPTION:Lurbinectedin\, phase 3.\nStudy: Study of Lurbinectedin in Comb
 ination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment 
 in Participants With Metastatic Leiomyosarcoma (SaLuDo)\nEstimated primary
  completion: 30 August 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/lurbinectedin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06088290
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
